These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28366579)

  • 1. Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study.
    Rijkmans EC; Cats A; Nout RA; van den Bongard DHJG; Ketelaars M; Buijsen J; Rozema T; Franssen JH; Velema LA; van Triest B; Marijnen CAM
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):908-917. PubMed ID: 28366579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study.
    Rijkmans EC; van Triest B; Nout RA; Kerkhof EM; Buijsen J; Rozema T; Franssen JH; Velema LA; Laman MS; Cats A; Marijnen CAM
    Radiother Oncol; 2018 Mar; 126(3):417-423. PubMed ID: 29398154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.
    Rijkmans EC; Marijnen CAM; van Triest B; Ketelaars M; Cats A; Inderson A; van den Ende RPJ; Laman MS; Kerkhof EM; Nout RA
    Radiother Oncol; 2019 Apr; 133():176-182. PubMed ID: 30935576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients.
    Chiang CL; Lee SF; Lee VW; Yeung CS; Cheung SK; Poon MC; Foo DC; Lo SH; Lam KO; Lee FA; Wong FC; Chan MK
    Strahlenther Onkol; 2020 Nov; 196(11):993-997. PubMed ID: 32313964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience.
    Sun Myint A; Smith FM; Gollins S; Wong H; Rao C; Whitmarsh K; Sripadam R; Rooney P; Hershman M; Pritchard DM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):565-573. PubMed ID: 29229327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study.
    Vuong T; Belliveau PJ; Michel RP; Moftah BA; Parent J; Trudel JL; Reinhold C; Souhami L
    Dis Colon Rectum; 2002 Nov; 45(11):1486-93; discussion 1493-5. PubMed ID: 12432296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma.
    Hoskin PJ; de Canha SM; Bownes P; Bryant L; Glynne Jones R
    Radiother Oncol; 2004 Nov; 73(2):195-8. PubMed ID: 15542167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial.
    Ortholan C; Romestaing P; Chapet O; Gerard JP
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e165-71. PubMed ID: 22579379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Dose-Rate Brachytherapy in the Management of Operable Rectal Cancer: A Systematic Review.
    Buckley H; Wilson C; Ajithkumar T
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):111-127. PubMed ID: 28816137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term outcome after neoadjuvant high-dose-rate endorectal brachytherapy or short-course external beam radiotherapy in resectable rectal cancer.
    Hesselager C; Vuong T; Påhlman L; Richard C; Liberman S; Letellier F; Folkesson J
    Colorectal Dis; 2013 Jun; 15(6):662-6. PubMed ID: 23461819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
    Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy?
    Garfinkle R; Lachance S; Vuong T; Mikhail A; Pelsser V; Gologan A; Morin NA; Vasilevsky CA; Boutros M
    Dis Colon Rectum; 2019 Mar; 62(3):294-301. PubMed ID: 30741768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients.
    Chuong MD; Fernandez DC; Shridhar R; Hoffe SE; Saini A; Hunt D; Meredith KL; Biagioli MC
    Brachytherapy; 2013; 12(5):457-62. PubMed ID: 23707855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer.
    Garant A; Magnan S; Devic S; Martin AG; Boutros M; Vasilevsky CA; Ferland S; Bujold A; DesGroseilliers S; Sebajang H; Richard C; Vuong T
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1005-1011. PubMed ID: 31476417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer.
    Koh WY; Lim K; Tey J; Lee KM; Lim GH; Choo BA
    Gynecol Oncol; 2013 Oct; 131(1):93-8. PubMed ID: 23906655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.